Bellerophon Therapeutics, Inc. (BLPH) reported top-line results from Phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for the treatment of fibrotic Interstitial Lung Disease.
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile. | June 5, 2023
Form S-3 Bellerophon Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.